By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

REPLICor Inc. 

1550 Metcalfe Street, Suite 502

Montreal  Quebec  H3A1X6  Canada
Phone: 514-842-9849 Fax: 514-842-1505


SEARCH JOBS








Company News
REPLICor Inc. To Make Three Presentations At EASL 2016 4/4/2016 11:00:58 AM
REPLICor Inc. To Present Pre-Clinical And Updated Clinical Data On REP 2139-Ca Based Combination Therapy In Chronic HBV And HBV / HDV Co-Infection At APASL 2016 2/16/2016 11:51:48 AM
REPLICor Inc. To Present Pre-Clinical And Clinical Data On REP 2139-Ca Based Combination Therapy In Chronic HBV / HDV Co-Infection At HEPDART 2015 12/1/2015 10:36:16 AM
REPLICor Inc. Discloses Continued Improvement Of The Antiviral Response In Patients With HBV / HDV Co-Infection Receiving REP 2139-Ca Based Combination Therapy 11/16/2015 10:16:12 AM
REPLICor Inc. Announces Publication Of Its Pre-Clinical Data On The Therapeutic Effect Of Naps On Hepatitis B Virus Infection 11/12/2015 12:35:25 PM
REPLICor Inc. Announces Grant Of US Patents On HBV / HDV Treatment Methods Combining HBsAg Reduction And Immunotherapy 11/9/2015 10:50:57 AM
REPLICor Inc. To Present An Update On The Safety And Efficacy Of REP 2139-Ca Based Combination Therapy In Chronic HBV / HDV Co-Infection At American Association for Study of Liver Diseases 2015 11/3/2015 10:49:25 AM
REPLICor Inc. Presents Updated Mechanistic Data And Pre-Clinical Interferon-Free Combination Treatment Data In HBV And HBV / HDV Co-Infection 10/15/2015 8:23:00 AM
REPLICor Inc. Announces Initiation Of Recruitment For Its Phase IIb Clinical Trial With REP 2139-Mg Or REP 2165-Mg In Combination With Viread And Pegasys Or Zadaxin In Patients With Hbeag Negative Chronic Hepatitis B Infection 10/5/2015 10:51:02 AM
REPLICor Inc. To Participate At The 6th DIA / FDA Oligonucleotide-Based Therapeutics Conference 9/3/2015 10:10:49 AM
12
//-->